Effect of Biliopancreatic Diversion on Glucose Homeostasis (BPD-Mingrone)
Primary Purpose
Obesity, Morbid
Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Roux-en-Y Gastric Bypass Surgery
Biliopancreatic Diversion Surgery
Sponsored by
About this trial
This is an interventional basic science trial for Obesity, Morbid focused on measuring Bariatric Surgery, Roux-en-Y gastric bypass, Biliopancreatic Diversion
Eligibility Criteria
Inclusion Criteria:
- Body Mass Index (BMI) ≥ 35 kg/m²
- Undergoing either the RYGB or the BPD procedure.
- Able to provide informed consent to participate in the research study
Exclusion Criteria:
- Weight > 450 pounds
- Smoke > 7 cigarettes per day
- Previous malabsorptive or restrictive intestinal surgery
- Pregnant or breastfeeding
- Inflammatory intestinal disease
- Diabetes
- Unstable dose of medications in the last 4 weeks before the pre-surgery metabolic studies
- Severe organ dysfunction
Sites / Locations
- Catholic University of the Sacred Heart
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
RYGB
BPD
Arm Description
Subjects received Roux-en-Y Gastric Bypass surgery.
Subjects received Biliopancreatic Diversion Surgery
Outcomes
Primary Outcome Measures
Change from baseline in skeletal muscle insulin sensitivity will be assessed using the Hyperinsulinemic-Euglycemic Clamp (HEC) procedure, before and after weight loss induced by either BPD or RYGB surgery
Insulin sensitivity: The HEC procedure will be used to evaluate insulin sensitivity before and after 20% weight loss induced by either BPD or RYGB surgery
Secondary Outcome Measures
Full Information
NCT ID
NCT03111953
First Posted
March 13, 2017
Last Updated
April 7, 2017
Sponsor
Washington University School of Medicine
Collaborators
Catholic University of the Sacred Heart, The Foundation for Barnes-Jewish Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03111953
Brief Title
Effect of Biliopancreatic Diversion on Glucose Homeostasis
Acronym
BPD-Mingrone
Official Title
Effect of Biliopancreatic Diversion on Glucose Homeostasis
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
January 9, 2014 (Actual)
Primary Completion Date
June 28, 2016 (Actual)
Study Completion Date
June 28, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine
Collaborators
Catholic University of the Sacred Heart, The Foundation for Barnes-Jewish Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Biliopancreatic diversion (BPD) surgery results in greater resolution of type 2 diabetes than all other bariatric surgical procedures, and it is hypothesized that this procedure has specific beneficial effects on glucose homeostasis beyond weight loss alone. The BPD procedure is performed in more than 150 patients/year by surgeons at the Division of Obesity and Metabolic Disorders, Catholic University of the Sacred Heart, School of Medicine, in Rome, Italy. The purpose of this study is to provide a better understanding of the effect of the BPD bariatric surgical procedure on insulin action and pancreatic beta cell function. It is hypothesized that weight loss achieved with BPD surgery will have greater effects on insulin sensitivity and beta cell function than weight loss induced by Roux-en-Y gastric bypass (RYGB).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Morbid
Keywords
Bariatric Surgery, Roux-en-Y gastric bypass, Biliopancreatic Diversion
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
RYGB
Arm Type
Active Comparator
Arm Description
Subjects received Roux-en-Y Gastric Bypass surgery.
Arm Title
BPD
Arm Type
Experimental
Arm Description
Subjects received Biliopancreatic Diversion Surgery
Intervention Type
Procedure
Intervention Name(s)
Roux-en-Y Gastric Bypass Surgery
Intervention Description
In Roux-en-Y Gastric Bypass Surgery a small gastric pouch is created and connected to a segment of jejunum. Bowel continuity is restored by reconnecting the "Roux" limb and the biliopancreatic limb approximately ~75-150 cm distal to the gastrojejunostomy. Therefore, ingested food bypasses most of the stomach, the entire duodenum, and a short segment of the jejunum.
Intervention Type
Procedure
Intervention Name(s)
Biliopancreatic Diversion Surgery
Intervention Description
In Biliopancreatic Diversion Surgery a horizontal gastrectomy is conducted leaving a portion of the stomach, which is connected to the small intestine, ~250 cm from the ileocecal valve and the biliopancreatic limb is connected to the ileum, ~50 cm from the ileocecal valve. Digestive secretions from the biliopancreatic limb mix in the common channel, where ingested food is also delivered by the alimentary limb.
Primary Outcome Measure Information:
Title
Change from baseline in skeletal muscle insulin sensitivity will be assessed using the Hyperinsulinemic-Euglycemic Clamp (HEC) procedure, before and after weight loss induced by either BPD or RYGB surgery
Description
Insulin sensitivity: The HEC procedure will be used to evaluate insulin sensitivity before and after 20% weight loss induced by either BPD or RYGB surgery
Time Frame
Change from Baseline up to a possible 9 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Body Mass Index (BMI) ≥ 35 kg/m²
Undergoing either the RYGB or the BPD procedure.
Able to provide informed consent to participate in the research study
Exclusion Criteria:
Weight > 450 pounds
Smoke > 7 cigarettes per day
Previous malabsorptive or restrictive intestinal surgery
Pregnant or breastfeeding
Inflammatory intestinal disease
Diabetes
Unstable dose of medications in the last 4 weeks before the pre-surgery metabolic studies
Severe organ dysfunction
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Samuel Klein, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Geltrude Mingrone, MD, PhD
Organizational Affiliation
Catholic University of the Sacred Heart
Official's Role
Principal Investigator
Facility Information:
Facility Name
Catholic University of the Sacred Heart
City
Rome
ZIP/Postal Code
00128
Country
Italy
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
32994312
Citation
Angelini G, Salinari S, Castagneto-Gissey L, Bertuzzi A, Casella-Mariolo J, Ahlin S, Boskoski I, Gaggini M, Raffaelli M, Costamagna G, Casella G, Marini PL, Gastaldelli A, Bornstein S, Mingrone G. Small intestinal metabolism is central to whole-body insulin resistance. Gut. 2021 Jun;70(6):1098-1109. doi: 10.1136/gutjnl-2020-322073. Epub 2020 Sep 29.
Results Reference
derived
PubMed Identifier
31588013
Citation
Harris LA, Kayser BD, Cefalo C, Marini L, Watrous JD, Ding J, Jain M, McDonald JG, Thompson BM, Fabbrini E, Eagon JC, Patterson BW, Mittendorfer B, Mingrone G, Klein S. Biliopancreatic Diversion Induces Greater Metabolic Improvement Than Roux-en-Y Gastric Bypass. Cell Metab. 2019 Nov 5;30(5):855-864.e3. doi: 10.1016/j.cmet.2019.09.002. Epub 2019 Oct 3.
Results Reference
derived
Learn more about this trial
Effect of Biliopancreatic Diversion on Glucose Homeostasis
We'll reach out to this number within 24 hrs